Tech Company Financing Transactions

Sibylla Biotech Funding Round

Sibylla Biotech closed a $22.7 million financing round on 10/4/2022. Investors included V-Bio Ventures, 3B Future Health Fund and CDP Venture Capital.

Transaction Overview

Company Name
Sibylla Biotech
Announced On
10/4/2022
Transaction Type
Venture Equity
Amount
$22,680,000
Round
Undisclosed
Investors

V-Bio Ventures (Lead Investor)

3B Future Health Fund (Marianne Bjordal)

CDP Venture Capital

Claris Ventures (Ciro Spedaliere)

Evolution Capital

Indaco Venture Partners

Seroba Life Sciences (Bruno Montanari)

Vertis SGR

VI Partners

Proceeds Purpose
The company intends to use the capital for the further development of its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) approach, which provides access to a new class of pharmacological targets that transiently appear during the process of protein folding, and to advance its proprietary pipeline programs through preclinical evaluation. The proceeds will allow the company to build out its pipeline of therapeutics by exploiting the protein folding simulation platform, as well as to further expand the potentiality of its technology.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Via Sommarive, 9, Trento, Trentino-Alto
Adige, 38123
IT
Phone
Undisclosed
Website
www.sibyllabiotech.it
Email Address
[email protected]
Overview
At Sibylla Biotech, we face the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs. Born out of a scientific challenge, the PPI-FIT protocol (Pharmacological Protein Inactivation by Folding Intermediates Targeting) leverages the enabling breakthrough of performing atomistic protein folding pathways simulations to unveil a new class of folding interfering degraders. Sibylla's drugs are small-molecule protein degraders, and PPI-FIT applies to any therapeutic area.
Profile
Sibylla Biotech LinkedIn Company Profile
Social Media
Sibylla Biotech Company Twitter Account
Company News
Sibylla Biotech News
Facebook
Sibylla Biotech on Facebook
YouTube
Sibylla Biotech on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Lidia Pieri
  Lidia Pieri LinkedIn Profile  Lidia Pieri Twitter Account  Lidia Pieri News  Lidia Pieri on Facebook
Co-Founder
Graziano Lolli
  Graziano Lolli LinkedIn Profile  Graziano Lolli Twitter Account  Graziano Lolli News  Graziano Lolli on Facebook
Co-Founder
Giovanni Spagnolli
  Giovanni Spagnolli LinkedIn Profile  Giovanni Spagnolli Twitter Account  Giovanni Spagnolli News  Giovanni Spagnolli on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/4/2022: Tidal Cyber venture capital transaction
Next: 10/4/2022: Vergent Bioscience venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.